The Motley Fool·1d ago
Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the EvidenceSome of Eli Lilly's products beyond its core therapeutic area are performing well. It also boasts a deep and diversified pipeline.
Eli Lilly's revenue climbed from $11.3B in 2024Q2 to $24.4B in 2026Q3, with year-over-year growth peaking near 55.5% in 2026Q1 before moderating to 38.6%, while gross margins have stayed anchored between 80.8% and 85.8%.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue scaled more than twofold over the ten-quarter window while gross margin held near 84% (83.9% in 2026Q3), yet operating margin fell from 47.6% in 2025Q3 to 35.3% in 2026Q3, indicating operating income is growing more slowly than revenue.
Eli Lilly reported a 56% year-over-year revenue increase to $19.8 billion in Q1 2026, with EPS up 170% to $8.26.
Mounjaro and Zepbound are projected to generate over $50 billion in revenue in 2026, with Foundayo expected to earn $1.6 billion.
Eli Lilly's $50 billion investment in manufacturing and a deep pipeline, including retatrutide, positions it for sustained leadership.
The stock's P/E ratio of 40.5x is significantly higher than the industry average of 16.1x, leaving little room for error.
The GLP-1 market faces threats from competitors like Novo Nordisk, with oral Wegovy potentially offering superior weight loss benefits.
Risks for drugs like Kisunla include bottlenecks in patient diagnosis and potential cannibalization of existing products.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $7.48+31.0% vs $5.71 | $24.4B+8.0% vs $22.6B |
Q3 2026 Aug 5, 2026 | $8.38+30.9% vs $6.40 | $23.0B+10.3% vs $20.8B |
Q2 2026 Apr 30, 2026 | $8.55+22.7% vs $6.97 | $19.8B+11.1% vs $17.8B |
Q1 2026 Feb 4, 2026 | $7.54+9.1% vs $6.91 | $19.3B+7.5% vs $17.9B |
Some of Eli Lilly's products beyond its core therapeutic area are performing well. It also boasts a deep and diversified pipeline.
On Friday, Eli Lilly And Co. (NYSE:LLY) and Hims & Hers Health Inc. (NYSE:HIMS) announced a collaboration to broaden patient access to obesity medications Zepbound and Foundayo through the digital health platform.
The best mutual funds place massive bets on Microsoft, Palantir and Apple. But that's just the start.
Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform.
Benchmark LLY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Eli Lilly and Company (LLY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1354.00 | $1.28T | 59.00 | 44.7% | 31.66% | 101.15% | 0.44% | |
| $40.31 | $179B | 11.71 | 6.43% | 35.35% | 59.09% | 4.32% | |
| $29.39 | $167.51B | 21.61 | -1.65% | 6.34% | 4.59% | 5.85% | |
| $146.71 | $362.35B | 20.15 | 1.18% | 4.78% | 6.59% | 2.22% | |
| $186.43 | $144.48B | 14.25 | 8.63% | 17.68% | 22.18% | 3.41% | |
| $62.14 | $126.89B | 18.01 | -0.22% | 18.47% | 43.84% | 3.98% |
Eli Lilly and Company (LLY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Eli Lilly and Company (LLY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Aug 5, 2026·SEC
May 20, 2026·SEC
Feb 12, 2026·SEC
Get notified when LLY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Eli Lilly and Company (LLY) stock FAQ — growth, dividends, profitability & financials explained
Eli Lilly and Company (LLY) reported $86.46B in revenue over the trailing twelve months. Revenue was $65.18B in fiscal year 2025. That is 831% more than the $7.00B of fiscal year 1996.
Eli Lilly and Company (LLY) grew revenue by 44.7% in fiscal year 2025, compared with the prior fiscal year.
Yes. Eli Lilly and Company (LLY) earned $27.58B in net income over the trailing twelve months (a 31.9% net margin).
Yes. Eli Lilly and Company (LLY) pays a dividend that yields 0.44% at the current price, a small yield.
Eli Lilly and Company (LLY) had a return on equity (ROE) of 101.2% in fiscal year 2025. That is well above the market's typical 10-15%.
Eli Lilly and Company (LLY) generated $19.66B in free cash flow over the trailing twelve months.
